An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease

Naoki Yoshimura, Yoko Yokoyama, Katsuyoshi Matsuoka, Hiroki Takahashi, Ryuichi Iwakiri, Takayuki Yamamoto, Tomoo Nakagawa, Takumi Fukuchi, Satoshi Motoya, Reiko Kunisaki, Shingo Kato, Fumihito Hirai, Yoh Ishiguro, Satoshi Tanida, Sakiko Hiraoka, Keiichi Mitsuyama, Shunji Ishihara, Shinji Tanaka, Michiro Otaka, Taro OsadaTakashi Kagaya, Yasuo Suzuki, Hiroshi Nakase, Hiroyuki Hanai, Kenji Watanabe, Nobuhito Kashiwagi, Toshifumi Hibi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn's disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD. Methods: In an open-label, prospective, randomized multicentre setting, 104 patients with CD activity index (CDAI) of 200 to 450 received intensive GMA, at two sessions per week (n = 55) or one session per week (n = 49). Clinical remission was defined as a CDAI score

Original languageEnglish
Article number163
JournalBMC Gastroenterology
Volume15
Issue number1
DOIs
Publication statusPublished - Nov 19 2015

Fingerprint

Blood Component Removal
Granulocytes
Crohn Disease
Multicenter Studies
Monocytes
Safety
Therapeutics

Keywords

  • C-reactive protein
  • Crohn's disease
  • Erythrocyte sedimentation rate
  • Granulocyte and monocyte adsorptive apheresis
  • Intensive therapy
  • Leucocyte count
  • Prospective study

ASJC Scopus subject areas

  • Gastroenterology

Cite this

An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. / Yoshimura, Naoki; Yokoyama, Yoko; Matsuoka, Katsuyoshi; Takahashi, Hiroki; Iwakiri, Ryuichi; Yamamoto, Takayuki; Nakagawa, Tomoo; Fukuchi, Takumi; Motoya, Satoshi; Kunisaki, Reiko; Kato, Shingo; Hirai, Fumihito; Ishiguro, Yoh; Tanida, Satoshi; Hiraoka, Sakiko; Mitsuyama, Keiichi; Ishihara, Shunji; Tanaka, Shinji; Otaka, Michiro; Osada, Taro; Kagaya, Takashi; Suzuki, Yasuo; Nakase, Hiroshi; Hanai, Hiroyuki; Watanabe, Kenji; Kashiwagi, Nobuhito; Hibi, Toshifumi.

In: BMC Gastroenterology, Vol. 15, No. 1, 163, 19.11.2015.

Research output: Contribution to journalArticle

Yoshimura, N, Yokoyama, Y, Matsuoka, K, Takahashi, H, Iwakiri, R, Yamamoto, T, Nakagawa, T, Fukuchi, T, Motoya, S, Kunisaki, R, Kato, S, Hirai, F, Ishiguro, Y, Tanida, S, Hiraoka, S, Mitsuyama, K, Ishihara, S, Tanaka, S, Otaka, M, Osada, T, Kagaya, T, Suzuki, Y, Nakase, H, Hanai, H, Watanabe, K, Kashiwagi, N & Hibi, T 2015, 'An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease', BMC Gastroenterology, vol. 15, no. 1, 163. https://doi.org/10.1186/s12876-015-0390-3
Yoshimura, Naoki ; Yokoyama, Yoko ; Matsuoka, Katsuyoshi ; Takahashi, Hiroki ; Iwakiri, Ryuichi ; Yamamoto, Takayuki ; Nakagawa, Tomoo ; Fukuchi, Takumi ; Motoya, Satoshi ; Kunisaki, Reiko ; Kato, Shingo ; Hirai, Fumihito ; Ishiguro, Yoh ; Tanida, Satoshi ; Hiraoka, Sakiko ; Mitsuyama, Keiichi ; Ishihara, Shunji ; Tanaka, Shinji ; Otaka, Michiro ; Osada, Taro ; Kagaya, Takashi ; Suzuki, Yasuo ; Nakase, Hiroshi ; Hanai, Hiroyuki ; Watanabe, Kenji ; Kashiwagi, Nobuhito ; Hibi, Toshifumi. / An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. In: BMC Gastroenterology. 2015 ; Vol. 15, No. 1.
@article{fe5e4aa2dff843ba9bf31002553cb80f,
title = "An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease",
abstract = "Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn's disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD. Methods: In an open-label, prospective, randomized multicentre setting, 104 patients with CD activity index (CDAI) of 200 to 450 received intensive GMA, at two sessions per week (n = 55) or one session per week (n = 49). Clinical remission was defined as a CDAI score",
keywords = "C-reactive protein, Crohn's disease, Erythrocyte sedimentation rate, Granulocyte and monocyte adsorptive apheresis, Intensive therapy, Leucocyte count, Prospective study",
author = "Naoki Yoshimura and Yoko Yokoyama and Katsuyoshi Matsuoka and Hiroki Takahashi and Ryuichi Iwakiri and Takayuki Yamamoto and Tomoo Nakagawa and Takumi Fukuchi and Satoshi Motoya and Reiko Kunisaki and Shingo Kato and Fumihito Hirai and Yoh Ishiguro and Satoshi Tanida and Sakiko Hiraoka and Keiichi Mitsuyama and Shunji Ishihara and Shinji Tanaka and Michiro Otaka and Taro Osada and Takashi Kagaya and Yasuo Suzuki and Hiroshi Nakase and Hiroyuki Hanai and Kenji Watanabe and Nobuhito Kashiwagi and Toshifumi Hibi",
year = "2015",
month = "11",
day = "19",
doi = "10.1186/s12876-015-0390-3",
language = "English",
volume = "15",
journal = "BMC Gastroenterology",
issn = "1471-230X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease

AU - Yoshimura, Naoki

AU - Yokoyama, Yoko

AU - Matsuoka, Katsuyoshi

AU - Takahashi, Hiroki

AU - Iwakiri, Ryuichi

AU - Yamamoto, Takayuki

AU - Nakagawa, Tomoo

AU - Fukuchi, Takumi

AU - Motoya, Satoshi

AU - Kunisaki, Reiko

AU - Kato, Shingo

AU - Hirai, Fumihito

AU - Ishiguro, Yoh

AU - Tanida, Satoshi

AU - Hiraoka, Sakiko

AU - Mitsuyama, Keiichi

AU - Ishihara, Shunji

AU - Tanaka, Shinji

AU - Otaka, Michiro

AU - Osada, Taro

AU - Kagaya, Takashi

AU - Suzuki, Yasuo

AU - Nakase, Hiroshi

AU - Hanai, Hiroyuki

AU - Watanabe, Kenji

AU - Kashiwagi, Nobuhito

AU - Hibi, Toshifumi

PY - 2015/11/19

Y1 - 2015/11/19

N2 - Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn's disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD. Methods: In an open-label, prospective, randomized multicentre setting, 104 patients with CD activity index (CDAI) of 200 to 450 received intensive GMA, at two sessions per week (n = 55) or one session per week (n = 49). Clinical remission was defined as a CDAI score

AB - Background: Granulocyte and monocyte adsorptive apheresis (GMA) has shown efficacy in patients with active Crohn's disease (CD). However, with routine weekly therapy, it may take several weeks to achieve remission. This study was performed to assess clinical efficacy and safety of intensive GMA in patients with active CD. Methods: In an open-label, prospective, randomized multicentre setting, 104 patients with CD activity index (CDAI) of 200 to 450 received intensive GMA, at two sessions per week (n = 55) or one session per week (n = 49). Clinical remission was defined as a CDAI score

KW - C-reactive protein

KW - Crohn's disease

KW - Erythrocyte sedimentation rate

KW - Granulocyte and monocyte adsorptive apheresis

KW - Intensive therapy

KW - Leucocyte count

KW - Prospective study

UR - http://www.scopus.com/inward/record.url?scp=84947736087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947736087&partnerID=8YFLogxK

U2 - 10.1186/s12876-015-0390-3

DO - 10.1186/s12876-015-0390-3

M3 - Article

C2 - 26585569

AN - SCOPUS:84947736087

VL - 15

JO - BMC Gastroenterology

JF - BMC Gastroenterology

SN - 1471-230X

IS - 1

M1 - 163

ER -